Join the club for FREE to access the whole archive and other member benefits.

New drug slowed tumour growth in men with prostate cancer

30-Sep-2019

Key points from article :

Olaparib is the first genetically targeted drug for fighting prostate cancer.

Drug works by targeting and killing cancer cells with faulty genetic code.

Olaparib could be made available to patients in the next couple of years.

Drug is also called Lynparza and made by AstraZeneca.

Olaparib delays cancer growth by months, which means the increased lifespan

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Institute

Independent cancer charity focused on saving lives through research, influence and information

Academic

Consultant at the Institute of Cancer Research

Academic

Deputy Director of Research at Prostate Cancer UK

Academic

Professor of Clinical Oncology specialising in urological cancer.

Company

Care for people with prostate cancer.

Institute

One of the world’s most influential cancer research organizations